[Nation-wide survey for the treatment with cyclosporin A of interstitial pneumonia associated with collagen diseases].

Ryumachi. [Rheumatism] Pub Date : 1999-12-01
M Harigai, M Hara, N Kamatani, S Kashiwazaki
{"title":"[Nation-wide survey for the treatment with cyclosporin A of interstitial pneumonia associated with collagen diseases].","authors":"M Harigai,&nbsp;M Hara,&nbsp;N Kamatani,&nbsp;S Kashiwazaki","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study was performed to investigate the efficacy and safety of cyclosporin A (CsA) for the treatment of interstitial pneumonia (IP) associated with collagen diseases in Japan.</p><p><strong>Methods: </strong>Questionnaires were sent to 36 hospitals specializing in collagen diseases.</p><p><strong>Results: </strong>Fifty-eight patients (7 polymyositis (PM), 19 dermatomyositis (DM), 7 systemic sclerosis (SSc), 7 rheumatoid arthritis (RA), 2 mixed connective tissue disease (MCTD), 1 systemic lupus erythematosus (SLE) and 1 Sjögren's syndrome (SS), 1 RA + SSc, 2 PM + SSc, 1 DM + SLE, and 10 idiopathic interstitial pneumonia (IIP) with IP were treated with CsA at 14 hospitals. IP was classified into the acute or chronic type. In the PM/DM group (7 PM, 19 DM, 2 PM + SSC, 1 DM + SLE), 65.5% were the acute type. In the other collagen disease group (7 SSc, 7 RA, 2 MCTD, 1 SLE, 1 SS, and 1 RA + SSc) and IIP group, 36.8% and 50% were the acute type, respectively. Mean dosages of CsA were 3.7 +/- 1.3 mg/kg/day for the PM/DM group, 3.0 +/- 1.0 for the other collagen disease group, and 3.8 +/- 4.8 for the IIP group. Oral corticosteroids were administered in combination with CsA in 100, 73.7, and 70% of the patients with PM/DM, other collagen disease, and IIP groups, respectively. CsA was effective for 72.2, 33.3, and 25% of the acute IP cases in the PM/DM, other collagen disease, and IIP groups, respectively. CsA was effective for 50.0, 50.0, and 60.0% of chronic IP cases in the PM/DM, other collagen disease, and IIP groups, respectively. Twenty-three adverse effects were observed, but most of them ameliorated upon withdrawal or reduction of the CsA dose.</p><p><strong>Conclusion: </strong>CsA is effective for the treatment of acute type IP associated with collagen diseases, especially PM/DM. To perform a prospective multi-center trial, standards for the recruitment of patients, efficacy assessments, and trial course and treatment should be determined carefully.</p>","PeriodicalId":76507,"journal":{"name":"Ryumachi. [Rheumatism]","volume":"39 6","pages":"819-28"},"PeriodicalIF":0.0000,"publicationDate":"1999-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ryumachi. [Rheumatism]","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: This study was performed to investigate the efficacy and safety of cyclosporin A (CsA) for the treatment of interstitial pneumonia (IP) associated with collagen diseases in Japan.

Methods: Questionnaires were sent to 36 hospitals specializing in collagen diseases.

Results: Fifty-eight patients (7 polymyositis (PM), 19 dermatomyositis (DM), 7 systemic sclerosis (SSc), 7 rheumatoid arthritis (RA), 2 mixed connective tissue disease (MCTD), 1 systemic lupus erythematosus (SLE) and 1 Sjögren's syndrome (SS), 1 RA + SSc, 2 PM + SSc, 1 DM + SLE, and 10 idiopathic interstitial pneumonia (IIP) with IP were treated with CsA at 14 hospitals. IP was classified into the acute or chronic type. In the PM/DM group (7 PM, 19 DM, 2 PM + SSC, 1 DM + SLE), 65.5% were the acute type. In the other collagen disease group (7 SSc, 7 RA, 2 MCTD, 1 SLE, 1 SS, and 1 RA + SSc) and IIP group, 36.8% and 50% were the acute type, respectively. Mean dosages of CsA were 3.7 +/- 1.3 mg/kg/day for the PM/DM group, 3.0 +/- 1.0 for the other collagen disease group, and 3.8 +/- 4.8 for the IIP group. Oral corticosteroids were administered in combination with CsA in 100, 73.7, and 70% of the patients with PM/DM, other collagen disease, and IIP groups, respectively. CsA was effective for 72.2, 33.3, and 25% of the acute IP cases in the PM/DM, other collagen disease, and IIP groups, respectively. CsA was effective for 50.0, 50.0, and 60.0% of chronic IP cases in the PM/DM, other collagen disease, and IIP groups, respectively. Twenty-three adverse effects were observed, but most of them ameliorated upon withdrawal or reduction of the CsA dose.

Conclusion: CsA is effective for the treatment of acute type IP associated with collagen diseases, especially PM/DM. To perform a prospective multi-center trial, standards for the recruitment of patients, efficacy assessments, and trial course and treatment should be determined carefully.

[环孢素A治疗胶原蛋白病相关性间质性肺炎的全国调查]。
目的:本研究旨在探讨环孢素A (CsA)治疗胶原蛋白相关的间质性肺炎(IP)的有效性和安全性。方法:对36家胶原蛋白病专科医院进行问卷调查。结果:对14家医院58例患者(多发性肌炎(PM) 7例、皮肌炎(DM) 19例、系统性硬化症(SSc) 7例、类风湿性关节炎(RA) 7例、混合性结缔组织病(MCTD) 2例、系统性红斑狼疮(SLE) 1例、Sjögren综合征(SS) 1例、RA + SSc 1例、PM + SSc 2例、DM + SLE 1例、特发性间质性肺炎(IIP)合并IP 10例)进行CsA治疗。IP分为急性型和慢性型。在PM/DM组(7 PM, 19 DM, 2 PM + SSC, 1 DM + SLE)中,65.5%为急性型。其他胶原病变组(SSc 7例、RA 7例、MCTD 2例、SLE 1例、SS 1例、RA + SSc 1例)和IIP组急性型分别为36.8%和50%。CsA的平均剂量PM/DM组为3.7 +/- 1.3 mg/kg/天,其他胶原疾病组为3.0 +/- 1.0 mg/kg/天,IIP组为3.8 +/- 4.8 mg/kg/天。口服皮质类固醇联合CsA分别用于100,73.7%和70%的PM/DM、其他胶原蛋白疾病和IIP组患者。CsA对PM/DM组、其他胶原蛋白疾病组和IIP组急性IP病例的有效率分别为72.2%、33.3%和25%。CsA对PM/DM、其他胶原蛋白疾病和IIP组慢性IP患者的有效率分别为50.0%、50.0%和60.0%。观察到23种不良反应,但大多数不良反应在停药或减少CsA剂量后得到改善。结论:CsA可有效治疗急性型IP合并胶原蛋白疾病,尤其是PM/DM。要进行前瞻性多中心试验,应仔细确定患者招募、疗效评估、试验过程和治疗的标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信